四种超声风险分层系统下不必要的甲状腺结节活检率:系统评价与Meta分析
该系统评价与Meta分析纳入8篇文献共13,092个甲状腺结节,比较ACR-TIRADS、ATA、EU-TIRADS和K-TIRADS的不必要活检率。ACR-TIRADS的不必要活检率为25%,显著低于ATA的51%和K-TIRADS的55%,也低于EU-TIRADS的38%但未达统计学显著;ACR-TIRADS、ATA和K-TIRADS的诊断比值比无显著差异。
要点
- ACR-TIRADS不必要活检率25%,显著低于ATA(51%)和K-TIRADS(55%)。
- ACR-TIRADS与EU-TIRADS不必要活检率比较未达统计学显著(p=.087)。
- ACR-TIRADS、ATA和K-TIRADS的诊断比值比无显著差异。
诊断标准与关键数值
- ACR-TIRADS不必要活检率25%(95% CI,22-29%)。
- ATA不必要活检率51%(95% CI,44-58%)。
- EU-TIRADS不必要活检率38%(95% CI,16-66%)。
- K-TIRADS不必要活检率55%(95% CI,42-67%)。
- ACR-TIRADS诊断比值比5.9(95% CI,3.6-9.6),ATA为6.3(95% CI,4.5-8.8),K-TIRADS为4.5(95% CI,1.7-11.6),差异无统计学显著。
临床应用与阅片要点
- 作者认为未来各系统的修订应参考ACR-TIRADS以减少不必要活检率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To summarize and compare unnecessary biopsy rates and diagnostic performance in the examination of thyroid nodules according to four representative US-based risk stratification systems.
METHODS: MEDLINE/PubMed and EMBASE databases were searched to identify original articles investigating unnecessary biopsy rates according to at least one of the following guidelines: ACR-TIRADS, ATA, EU-TIRADS, and K-TIRADS. The unnecessary biopsy rates for each risk stratification system were pooled using a random-effects model. Meta-regression analyses were performed to explore heterogeneity. Diagnostic odds ratios (DORs) for the appropriate selection of thyroid nodules for fine-needle aspiration were also pooled using a bivariate random-effects model.
RESULTS: Eight articles including 13,092 thyroid nodules met the eligibility criteria and were included. The pooled unnecessary biopsy rates of ACR-TIRADS, ATA, EU-TIRADS, and K-TIRADS were 25% (95% CI, 22-29%), 51% (95% CI, 44-58%), 38% (95% CI, 16-66%), and 55% (95% CI, 42-67%), respectively. The pooled unnecessary biopsy rate of ACR-TIRADS was significantly lower than that of ATA (p < .001) and K-TIRADS (p < .001), and also lower than that of EU-TIRADS, but not reaching statistical significance (p = .087). The pooled DORs of ACR-TIRADS, ATA, and K-TIRADS were 5.9 (95% CI, 3.6-9.6), 6.3 (95% CI, 4.5-8.8), and 4.5 (95% CI, 1.7-11.6), respectively, with the differences not being statistically significant.
CONCLUSIONS: ACR-TIRADS showed a lower unnecessary biopsy rate than the other risk stratification systems albeit DOR was comparable between ACR-TIRADS, ATA, and K-TIRADS. Future revisions of each system should be made by referring to ACR-TIRADS to reduce unnecessary biopsy rates.
KEY POINTS: • The pooled unnecessary biopsy rates of ACR-TIRADS, ATA, EU-TIRADS, and K-TIRADS were 25% (95% CI, 22-29%), 51% (95% CI, 44-58%), 38% (95% CI, 16-66%), and 55% (95% CI, 42-67%), respectively. • The pooled unnecessary biopsy rate of ACR-TIRADS was significantly lower than that of ATA (p < .001) and K-TIRADS (p < .001). • The pooled DORs of ACR-TIRADS, ATA, and K-TIRADS were 5.9 (95% CI, 3.6-9.6), 6.3 (95% CI, 4.5-8.8), and 4.5 (95% CI, 1.7-11.6), respectively, with the differences not being statistically significant.
引用
- Kim PH, Suh CH, Baek JH, et al. Unnecessary thyroid nodule biopsy rates under four ultrasound risk stratification systems: a systematic review and meta-analysis. Eur Radiol. 2020. PMID: 33057762. doi:10.1007/s00330-020-07384-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。